Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies-Reference-Cited by-同舟云学术

Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies

Published:2003-06 Issue:6 Volume:14 Page:913-921
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Braybrooke J.P.,Boven E.,Bates N.P.,Ruijter R.,Dobbs N.,Cheverton P.D.,Pinedo H.M.,Talbot D.C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/14/6/913/364804/mdg243.pdf

Reference35 articles.

1. Plant antitumour agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata;Wall;J Am Chem Soc,1966

2. Action of camptothecin on mammalian cells in culture;Li;Cancer Res,1972

3. Lethal activity of camptothecin sodium on human lymphoma cells;Drewinko;Cancer Res,1974

4. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin;Gallo;J Natl Cancer Inst,1971

5. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin;Eng;Mol Pharmacol,1988

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates;Oncology Research and Treatment;2023-11-28

2. A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors;Cancer Research Communications;2023-05-24

3. Antibody-drug Conjugate Targets, Drugs, and Linkers;Current Cancer Drug Targets;2022-07

4. Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature;Molecular Pharmaceutics;2010-03-02

5. Recent developments in the clinical activity of topoisomerase-1 inhibitors;Update on Cancer Therapeutics;2006-06